These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26663410)

  • 21. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
    Lalezari S; Reding MT; Pabinger I; Holme PA; Negrier C; Chalasani P; Shin HJ; Wang M; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2019 Nov; 25(6):1011-1019. PubMed ID: 31621991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.
    Mahlangu J; Lopez Fernandez MF; Santagostino E; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Church N
    Eur J Haematol; 2020 Jun; 104(6):594-601. PubMed ID: 32112434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.
    Matysiak M; Bobrowska H; Balwierz W; Chybicka A; Kowalczyk JR; Shaikh-Zaidi R; Gillanders K; Dash CH
    Haemophilia; 2011 Sep; 17(5):737-42. PubMed ID: 21699629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
    Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
    Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.
    Nijdam A; Kurnik K; Liesner R; Ljung R; Nolan B; Petrini P; Fischer K;
    Haemophilia; 2015 Jul; 21(4):444-50. PubMed ID: 25582494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAY 81-8973 (Octocog Alfa; Kovaltry
    Keating GM
    BioDrugs; 2016 Oct; 30(5):453-459. PubMed ID: 27577234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
    Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
    Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.
    Vepsäläinen K; Lassila R; Arola M; Huttunen P; Koskinen S; Ljung R; Lähteenmäki P; Möttönen M; Riikonen P
    Haemophilia; 2016 Sep; 22(5):721-9. PubMed ID: 27339837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
    Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
    J Thromb Haemost; 2024 Jul; 22(7):1880-1893. PubMed ID: 38614387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
    Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
    J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
    Kruse-Jarres R; Oldenburg J; Santagostino E; Shima M; Kempton CL; Kessler CM; Lehle M; Chebon S; Selak Bienz N; Asikanius E; Mahlangu J
    Haemophilia; 2019 Mar; 25(2):213-220. PubMed ID: 30724422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
    Klamroth R; Windyga J; Radulescu V; Collins PW; Stasyshyn O; Ibrahim HM; Engl W; Tangada SD; Savage W; Ewenstein B
    Blood; 2021 Apr; 137(13):1818-1827. PubMed ID: 33150384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
    Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
    Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.